论文部分内容阅读
四川省肿瘤研究所助理研究员卢绍平等在国内首次采用基因工程技术以全移Ha-ras癌基因的表达产物P_(21)蛋白研制的单克隆抗体于1992年1月15日通过了省级鉴定。该抗体具有比国内同类抗体效价高(达10~(-7))、特异性强、稳定性好、质量可靠、价格低等优点。经华西医科大学、湖北医学院等多家科研、教学单位应用表明,P_(21)蛋白在癌组织的表达明
Lu Shaoping, an assistant researcher at the Sichuan Provincial Cancer Institute, passed the provincial appraisal on January 15, 1992 for the first time that a genetically engineered monoclonal antibody developed by genetically engineered Ha-ras oncogene expression product P_(21) protein was used in China. . The antibody has the advantages of higher titer (up to 10~(-7)), better specificity, better stability, reliable quality, and lower price than similar domestic antibodies. The applications of P_(21) protein in cancer tissues have been demonstrated by a number of scientific research and teaching units in West China Medical University and Hubei Medical College.